Raya Therapeutic
- Biotech or pharma, therapeutic R&D
Company is focused on developing drugs to treat ALS. The company has secured 5 clinical stage compounds with different MOAs that all have potential to treat ALS. The company has a unique collaboration with argenx ($35B market cap) to develop combination therapies for ALS. Raya plans to start as many as 7 different clinical trials in 2025/2026.
The company is currently seeking investors for its Series B round as well as potential licensing partners for some of its 5 late stage compounds.